BTIG analyst Sam Eiber has maintained their neutral stance on APYX stock, giving a Hold rating on September 30.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sam Eiber’s rating is based on a combination of factors surrounding Apyx Medical’s current market position and the potential of its new Ayon body contouring system. While the Ayon system has received positive feedback from early adopters and shows promise in enhancing clinical efficiency and patient outcomes, the broader macroeconomic environment for aesthetic capital equipment remains challenging. This environment might limit the immediate adoption of the Ayon system despite its innovative features and potential benefits.
Additionally, Apyx Medical’s valuation is assessed on an EV/Sales basis, and the firm does not provide price targets for Neutral-rated stocks. The demand for Ayon is primarily from existing customers, which indicates a positive reception but also suggests that market expansion may be gradual. These factors contribute to a Hold rating, reflecting a cautious stance until further market conditions or company performance indicators suggest a more definitive growth trajectory.
According to TipRanks, Eiber is an analyst with an average return of -12.6% and a 18.18% success rate.
In another report released on September 30, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.